Organon (OGN) Gains from Sales and Divestitures (2024)
Organon (OGN) posted quarterly Gains from Sales and Divestitures of $56000.0 for Q4 2024.
Organon (OGN) Gains from Sales and Divestitures (2024) Analysis & Trends
Organon (OGN) has reported Gains from Sales and Divestitures for 1 consecutive years, with $56000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Gains from Sales and Divestitures changed N/A year-over-year to $56000.0; the TTM figure through Dec 2024 stood at $56000.0 (changed N/A YoY), while the FY2024 annual figure was $56000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures came in at $56000.0 for Q4 2024 at Organon.
- The five-year high for Gains from Sales and Divestitures was $56000.0 in Q4 2024, with the low at $56000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 56,000.00 |
| Dec 31, 2024 | 56,000.00 |